DE602004022632D1 - Verwendung von adiponectin zur diagnose von krebs - Google Patents
Verwendung von adiponectin zur diagnose von krebsInfo
- Publication number
- DE602004022632D1 DE602004022632D1 DE602004022632T DE602004022632T DE602004022632D1 DE 602004022632 D1 DE602004022632 D1 DE 602004022632D1 DE 602004022632 T DE602004022632 T DE 602004022632T DE 602004022632 T DE602004022632 T DE 602004022632T DE 602004022632 D1 DE602004022632 D1 DE 602004022632D1
- Authority
- DE
- Germany
- Prior art keywords
- cancer
- adiponectin
- diagnosis
- disclosed
- epithelial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000011690 Adiponectin Human genes 0.000 title abstract 4
- 108010076365 Adiponectin Proteins 0.000 title abstract 4
- 238000003745 diagnosis Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 201000009030 Carcinoma Diseases 0.000 abstract 3
- 206010014733 Endometrial cancer Diseases 0.000 abstract 3
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 229940124232 Adiponectin receptor agonist Drugs 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43908803P | 2003-01-09 | 2003-01-09 | |
PCT/US2004/000410 WO2004063711A2 (en) | 2003-01-09 | 2004-01-09 | Use of adiponectin to diagnose and treat malignancy |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004022632D1 true DE602004022632D1 (de) | 2009-10-01 |
Family
ID=32713428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004022632T Expired - Lifetime DE602004022632D1 (de) | 2003-01-09 | 2004-01-09 | Verwendung von adiponectin zur diagnose von krebs |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1585987B1 (de) |
AT (1) | ATE440284T1 (de) |
DE (1) | DE602004022632D1 (de) |
WO (1) | WO2004063711A2 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1671122B1 (de) * | 2003-09-27 | 2012-04-18 | Siemens Healthcare Diagnostics Inc. | Diagnostika und therapeutika für mit adiponectin receptor 2 (adipor2) assoziierten erkrankungen |
EP1685846B1 (de) * | 2003-11-04 | 2014-11-26 | Daiichi Sankyo Company, Limited | Antitumorales mittel |
US7749956B2 (en) | 2005-01-07 | 2010-07-06 | Xencor, Inc. | Method of treatment using adiponectin variants |
US7678886B2 (en) | 2005-01-07 | 2010-03-16 | Xencor, Inc. | Pharmaceutical compositions of adiponectin variants and methods of storage |
US7592423B2 (en) | 2005-01-07 | 2009-09-22 | Xencor, Inc. | Globular adiponectin variants |
US8093017B2 (en) | 2005-12-07 | 2012-01-10 | Siemens Heathcare Diagnostics Inc. | Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics |
CA2707182C (en) | 2007-11-30 | 2017-12-12 | Siemens Healthcare Diagnostics Inc. | Adiponectin receptor fragments and methods of use |
EP3444611A1 (de) * | 2009-04-23 | 2019-02-20 | Siemens Healthcare Diagnostics Inc. | Monomere und dimere formen von adiponectin-rezeptor-fragmenten sowie und verfahren zur verwendung davon |
KR102402428B1 (ko) * | 2021-06-18 | 2022-05-31 | 주식회사 레지온 | 난소암 진단용 다중 바이오 마커 및 이의 용도 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1000084A4 (de) * | 1997-07-08 | 2003-03-26 | Human Genome Sciences Inc | 123 vom menschen abgesonderte proteine |
FR2767135B1 (fr) * | 1997-08-06 | 2002-07-12 | Genset Sa | Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes |
EP1365022A4 (de) * | 2001-02-01 | 2004-04-28 | Mochida Pharm Co Ltd | Adiponectin-assoziiertes protein |
-
2004
- 2004-01-09 WO PCT/US2004/000410 patent/WO2004063711A2/en active Application Filing
- 2004-01-09 DE DE602004022632T patent/DE602004022632D1/de not_active Expired - Lifetime
- 2004-01-09 AT AT04701189T patent/ATE440284T1/de not_active IP Right Cessation
- 2004-01-09 EP EP04701189A patent/EP1585987B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1585987A2 (de) | 2005-10-19 |
EP1585987B1 (de) | 2009-08-19 |
WO2004063711A2 (en) | 2004-07-29 |
ATE440284T1 (de) | 2009-09-15 |
WO2004063711A3 (en) | 2004-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Di Palma et al. | Salivary duct carcinomas can be classified into luminal androgen receptor‐positive, HER2 and basal‐like phenotypes | |
ATE337011T1 (de) | Modifizierte psma-liganden und deren verwendung | |
DK2199801T3 (da) | Biomarkører til tidlig påvisning af ovariecancer | |
ATE430936T1 (de) | Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome | |
WO2006089212A3 (en) | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin | |
WO2005029137A3 (en) | Fiber opticlaser-induced breakdown spectroscopy device and methods of use | |
ATE365922T1 (de) | Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6) | |
SG165370A1 (en) | Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites | |
TW200626899A (en) | Frizzled proteins and detection and treatment of cancer | |
ATE459883T1 (de) | Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose | |
WO2006078911A3 (en) | Gitr antibodies for the diagnosis of nsclc | |
CA2701341A1 (en) | Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex | |
PL2211180T3 (pl) | Zastosowanie białka SATB2 jako markera do rozróżniania nowotworów jelita grubego od innych nowotworów | |
DE602004022632D1 (de) | Verwendung von adiponectin zur diagnose von krebs | |
Tsang et al. | Nerve growth factor receptor (NGFR): a potential marker for specific molecular subtypes of breast cancer | |
Gadducci et al. | Is perineural invasion a novel prognostic factor useful to tailor adjuvant treatment in patients treated with primary surgery for cervical and vulvar carcinoma? | |
ATE350662T1 (de) | Markerproteine für prostatakrebs | |
ATE545867T1 (de) | I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom | |
DE602005013430D1 (de) | Verwendung von asc als marker für kolorektalkarzinome | |
DE60335387D1 (de) | Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen | |
Mhawech-Fauceglia et al. | Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas | |
DE602004017317D1 (de) | Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome | |
DE602005027065D1 (de) | Verwendung neuartiger biomarker zum nachweis von hodenkrebs in situ und abgeleiteten krebserkrankungen in menschlichen proben | |
Vollmann‐Zwerenz et al. | Multichromatic phenotyping of HER receptor coexpression in breast tumor tissue samples using flow cytometry—possibilities and limitations | |
DE602004025812D1 (de) | N mammakarzinom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |